Product logins

Find logins to all Clarivate products below.


In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the reference brands Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Gene Therapy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…
Report
Gene Therapies for Rare Diseases | Disease Landscape & Forecast | G7 | 2025
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…
Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Epilepsy | Disease Landscape and Forecast | G7 | 2025
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…